Rapid Therapeutic Science Stock Today
| RTSL Stock | USD 0 0.00 0.00% |
Performance7 of 100
| Odds Of DistressLess than 12
|
Rapid Therapeutic is selling for 0.001 as of the 22nd of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.001. Rapid Therapeutic has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Rapid Therapeutic Science are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc. Rapid Therapeutic operates under Medical Devices classification in the United States and is traded on OTC Exchange. The company has 7.75 M outstanding shares. More on Rapid Therapeutic Science
Moving against Rapid Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Rapid Pink Sheet Highlights
| Business Concentration | Medical Devices, Healthcare (View all Sectors) |
Rapid Therapeutic Science [RTSL] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.22 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Rapid Therapeutic's market, we take the total number of its shares issued and multiply it by Rapid Therapeutic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Rapid Therapeutic Science conducts business under Healthcare sector and is part of Medical Devices industry. The entity has 7.75 M outstanding shares.
Rapid Therapeutic Science currently holds about 112.16 K in cash with (2.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Rapid Therapeutic Probability Of Bankruptcy
Ownership AllocationRapid Therapeutic holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 66.33 pct. of Rapid Therapeutic Science outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event.
Check Rapid Ownership Details
Rapid Therapeutic Science Risk Profiles
| Mean Deviation | 7.45 | |||
| Standard Deviation | 24.28 | |||
| Variance | 589.28 | |||
| Risk Adjusted Performance | 0.0755 |
Rapid Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Rapid Therapeutic without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Rapid Therapeutic Corporate Management
| Donal Schmidt | CEO Pres | Profile | |
| Duane Drinkwine | Chief Officer | Profile | |
| Hughes Watler | CFO Director | Profile | |
| Sean Berrier | VP | Profile | |
| Frank Gill | Chief Technician | Profile | |
| Ryan Johnson | VP Marketing | Profile |
Other Information on Investing in Rapid Pink Sheet
Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.